The pharmaceutical industry is characterized by years-long R&D cycles, as well as an acute need for speed when it comes to time-to-market. As a result, traditionally sales force automation and other backoffice automation services have been the main money earners when it comes to pharma outsourcing.
The advent of robotic process automation (RPA) in their field of pharmaceutical R&D and manufacturing promises to change the game, as using digital robots to perform high-volume and repeatable tasks, CROs and CMOs can execute recurring processes faster, and more efficiently. This is further accentuated by the fact that RPA solutions are easily implemented without impacting IT-managed infrastructure or technology resources, thereby saving companies considerable time and money while outsourcing.
To put the spotlight on such key developments in the industry, Pharma Tech Outlook APAC illustrates how CMOs and CROs are changing the pharma outsourcing space. This edition also features thought leadership articles from subject matter experts. Some of the exclusive insights are authored by Nick Thomson, Senior Director, Chemical Research and Development, Pfizer Inc; Dr. Sarah Tregenza PhD, BSc (Hons), APAC Oncology Medical Affairs Director, Pierre Fabre; and Dannarjaya Harinta Sri, VP Operations and Technology, PT Anugerah Pharmindo Lestari (APL).
In this edition of Pharma Tech Outlook, we also bring to you the story of the top pharma outsourcing companies in the APAC region developing innovative products such as non-monoclonal antibodies, novel small molecule drugs, and specialty injectables. In the list, Alithia LIfe Sciences stands out for offering clinical research consulting including feasibility, selection, and support of vendors, sites, and CROs to undertake a client’s project.
Through the following pages, we aim to shine a light on the innovative trends and latest developments in the pharma outsourcing space. We would like to know your thoughts.
